Stopping ocrelizumab in early relapsing multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early relapsing MS diagnosed within the last 3 years from your first symptoms
- You’ve had at least one MS episode confirmed by MS criteria (clinical exam, MRI, or specific spinal-fluid test)
- You can give written consent and follow the study plan
- If you could become pregnant, you must use reliable birth control during the study and for 6 months after the last dose
- You must be able to get MRIs (no implanted metal/electronic devices that block MRI)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This extension study continues treatment with ocrelizumab for people with multiple sclerosis who are already taking it as part of a parent trial, to see how MS affects physical function over a longer time. It helps ensure you can keep receiving ocrelizumab even if it's not available where you live.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.